Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upArndt Vogel, Erika Martinelli, Dirk Arnold et al.|Annals of Oncology|2018Cited by 1.1k
Somatic mutation of CDKN1B in small intestine neuroendocrine tumorsJoshua M. Francis, Matthew Meyerson, Adam Kieżun et al.|Nature Genetics|2013Cited by 374
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancerTim Meyer, Hiroki Kato, Martyn Caplin et al.|European Journal of Cancer|2009Cited by 39
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignanciesRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1